Tyr881
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr881  -  Pyk2 (human)

Site Information
DRTDDLVyLNVMELV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447958

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 ) , mutation of modification site ( 1 , 4 , 9 ) , phospho-antibody ( 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , western blotting ( 1 , 3 , 7 , 8 , 9 )
Disease tissue studied:
breast cancer ( 3 , 7 ) , esophageal cancer ( 2 ) , esophageal carcinoma ( 2 )
Relevant cell line - cell type - tissue:
DU4475 (breast cell) ( 7 ) , HeLa (cervical) ( 6 ) , HMVEC (endothelial) ( 4 ) , HUVEC (endothelial) ( 4 ) , Jurkat (T lymphocyte) ( 9 ) , KG-1 (myeloid) ( 5 ) , Kyse180 (esophageal) ( 2 ) , MCF-10A (breast cell) ( 3 ) , myeloid ( 5 ) , neutrophil ( 8 ) , VSMC ('muscle, smooth') ( 1 )

Upstream Regulation
Treatments:
A23187 ( 3 ) , BAPTA-AM ( 3 ) , BPDE ( 3 ) , CXCL12 ( 4 , 7 ) , proepithelin ( 8 ) , Slit ( 7 ) , TNF ( 8 ) , VEGF ( 4 )

Downstream Regulation
Effects of modification on Pyk2:
molecular association, regulation ( 1 )
Induce interaction with:
GRB2 (human) ( 1 )

References 

1

Xi G, Shen XC, Wai C, Clemmons DR (2013) Recruitment of Nox4 to a plasma membrane scaffold is required for localized reactive oxygen species generation and sustained Src activation in response to insulin-like growth factor-I. J Biol Chem 288, 15641-53
23612968   Curated Info

2

Tucker M (2010) CST Curation Set: 9227; Year: 2010; Biosample/Treatment: cell line, Kyse180/untreated; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Burdick AD, Ivnitski-Steele ID, Lauer FT, Burchiel SW (2006) PYK2 mediates anti-apoptotic AKT signaling in response to benzo[a]pyrene diol epoxide in mammary epithelial cells. Carcinogenesis 27, 2331-40
16774943   Curated Info

4

Kuwabara K, et al. (2004) Differential regulation of cell migration and proliferation through proline-rich tyrosine kinase 2 in endothelial cells. Endocrinology 145, 3324-30
15070849   Curated Info

5

Recher C, et al. (2004) Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 64, 3191-7
15126359   Curated Info

6

Shi CS, Kehrl JH (2004) Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation. J Biol Chem 279, 17224-31
14963038   Curated Info

7

Prasad A, Fernandis AZ, Rao Y, Ganju RK (2004) Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells. J Biol Chem 279, 9115-24
14645233   Curated Info

8

Zhu J, et al. (2002) Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111, 867-78
12526812   Curated Info

9

Katagiri T, et al. (2000) Protein-tyrosine kinase Pyk2 is involved in interleukin-2 production by Jurkat T cells via its tyrosine 402. J Biol Chem 275, 19645-52
10867021   Curated Info